JP2011515491A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515491A5
JP2011515491A5 JP2011502043A JP2011502043A JP2011515491A5 JP 2011515491 A5 JP2011515491 A5 JP 2011515491A5 JP 2011502043 A JP2011502043 A JP 2011502043A JP 2011502043 A JP2011502043 A JP 2011502043A JP 2011515491 A5 JP2011515491 A5 JP 2011515491A5
Authority
JP
Japan
Prior art keywords
inhibitors
hiv
crystalline form
ray diffraction
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011502043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515491A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/038362 external-priority patent/WO2009120841A1/en
Publication of JP2011515491A publication Critical patent/JP2011515491A/ja
Publication of JP2011515491A5 publication Critical patent/JP2011515491A5/ja
Pending legal-status Critical Current

Links

JP2011502043A 2008-03-27 2009-03-26 N−[[4−フルオロ−2−(5−メチル−1H−1,2,4−トリアゾール−1−イル)フェニル]メチル]−4,6,7,9−テトラヒドロ−3−ヒドロキシ−9,9−ジメチル−4−オキソ−ピリミド[2,1−c][1,4]オキサジン−2−カルボキシアミド,ナトリウム塩一水和物の結晶形 Pending JP2011515491A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3998908P 2008-03-27 2008-03-27
US61/039,989 2008-03-27
PCT/US2009/038362 WO2009120841A1 (en) 2008-03-27 2009-03-26 Crystalline form of n-[[4-fluoro-2-(5-methyl-1h-1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide, sodium salt monohydrate

Publications (2)

Publication Number Publication Date
JP2011515491A JP2011515491A (ja) 2011-05-19
JP2011515491A5 true JP2011515491A5 (enExample) 2012-03-01

Family

ID=41008867

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011502043A Pending JP2011515491A (ja) 2008-03-27 2009-03-26 N−[[4−フルオロ−2−(5−メチル−1H−1,2,4−トリアゾール−1−イル)フェニル]メチル]−4,6,7,9−テトラヒドロ−3−ヒドロキシ−9,9−ジメチル−4−オキソ−ピリミド[2,1−c][1,4]オキサジン−2−カルボキシアミド,ナトリウム塩一水和物の結晶形

Country Status (8)

Country Link
US (1) US7968541B2 (enExample)
EP (1) EP2280980B1 (enExample)
JP (1) JP2011515491A (enExample)
KR (1) KR20100138959A (enExample)
CN (1) CN102046637B (enExample)
AU (1) AU2009228254A1 (enExample)
MX (1) MX2010010244A (enExample)
WO (1) WO2009120841A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106478661A (zh) * 2015-08-25 2017-03-08 华北制药集团新药研究开发有限责任公司 苯并恶唑并恶嗪酮类化合物wa1-089的晶型e及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US7157447B2 (en) * 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7176196B2 (en) * 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
WO2007064316A1 (en) * 2005-11-30 2007-06-07 Bristol-Myers Squibb Company Bicyclic heterocycles as hiv integrase inhibitors
WO2007064502A1 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Forms of n-[(4-fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide
WO2007143446A1 (en) * 2006-05-30 2007-12-13 Bristol-Myers Squibb Company Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors

Similar Documents

Publication Publication Date Title
JP2018115191A5 (enExample)
RU2466129C2 (ru) Твердые формы рацемического илапразола
JP2010535785A5 (enExample)
JP2013518107A5 (enExample)
KR100757699B1 (ko) 순수한 결정형의 5-클로로-3-(4-메탄설포닐페닐)-6'-메틸-[2,3']비피리디닐 및 이의 합성 방법
ME02612B (me) Tenofovir alafenamid hemifumarat
JP2013536864A5 (enExample)
JP2010501478A5 (enExample)
JP2018024682A5 (enExample)
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
JP2008506720A5 (enExample)
JP2017526711A5 (enExample)
JP2015500843A5 (enExample)
JP2012530713A5 (enExample)
JP2009525287A5 (enExample)
JP2016190843A5 (enExample)
JP2012507535A5 (enExample)
JP2016535769A5 (enExample)
JP2013538849A5 (enExample)
JP2020536893A5 (enExample)
JP2016510768A5 (enExample)
JP2013517295A5 (enExample)
JP2019522628A5 (enExample)
JP2011527687A5 (enExample)
JP2008069182A5 (enExample)